Global injectable benzodiazepine sales are set to reach USD 260 million in 2020, as covid-19 panic and uncertainty has set in, even among population with […]
The post Injectable Benzodiazepine Market is Anticipated to Gain CAGR of 2.7% by 2030 first appeared on Market Research Blog.
Global injectable benzodiazepine sales are set to reach USD 260 million in 2020, as covid-19 panic and uncertainty has set in, even among population with no previous history of mental illnesses, according to a new study by Future Market Insights (FMI). The market research firm estimates the market to grow at 2.7% CAGR through 2030.
Although covid-19 will create a short-term spike, in the long run, the market is likely to be driven by increasing demand for generic drugs. Growing acceptance of injectables as a route of administration is also likely to drive growth.
Key Takeaways of Injectable Benzodiazepine Market Study
- Lorazepam injectable benzodiazepine accounted for the highest share in the injectable benzodiazepine market in 2019
- Seizures and anxiety among leading ailments where injectable benzodiazepines are administered
- North America and Europe are expected to hold a noteworthy revenue share of about 60% in the global injectable benzodiazepine market in 2020
Low cost manufacturing and large patient pools in Asian countries expected to be a key growth driver in the forecast period
“Growing incidences of seizures and anxiety followed by demand for generics to boost the global injectable benzodiazepine market,” says an FMI Analyst.
Request For Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-11724
Research Collaborations: Key to Sustenance
The market players are emphasizing on expanding their manufacturing facilities with introduction of cost-effective and generic drugs and also venturing into strategic partnerships.
- In Jan 2020, Hospital Sales Force from Xellia signed an agreement with Eton to promote Biorphen in the institutions that prefer having ready-to-use injectable formulations
- In Oct 2019, KemPharm’s APADAZ (to treat ADHD) got licensed to KVK-Tech, Inc. to make its generic AG-APADAZ available all across the US
- In Dec 2018, Hikma Pharmaceuticals came up with clobazam oral suspension as well as tablets, the generic equivalent to “Onfi” (marketed by H. Lundbeck A/S)
What else is in the report?
Future market insights offer a unique perspective and actionable insights on injectable benzodiazepine market in its latest study, presenting historical demand assessment from 2015 – 2019 and projections from 2020–2030 based on drug class (diazepam, lorazepam, and midazolam), by time of action (short acting long acting), by indication (agitation & aggression, anxiety, alcohol withdrawal, muscle spasm, seizures, tetanus, sedation, anesthesia insomnia, and status epilepticus), by distribution channel (hospital pharmacies, retail pharmacies and online pharmacies) in seven key regions.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Market Background
4.1. Macro-Economic Factors
4.1.1. Global GDP Growth Outlook
4.1.2. Per Capita Healthcare Expenditure Outlook
4.1.3. Overall Psychoactive Drugs Market
4.2. Forecast Factors – Relevance & Impact
4.2.1. Increasing Incidence of Anxiety, Seizures, Insomnia
4.2.2. Increasing Usage as Anaesthesia
4.2.3. Dose Per Case
4.2.4. Treatment Cost
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
5. Market Context
5.1. Product Adoption / Usage Analysis By Indication
5.2. Disease Epidemiology, By Region
5.3. Regulatory Scenario
5.4. Reimbursement Landscape
5.5. Key Promotional Strategies, By Manufacturers
5.6. COVID19 Crisis Analysis
5.6.1. Current COVID19 Statistics and Probable Future Impact
5.6.2. Current GDP Projection and Probable Impact
5.6.3. COVID19 and Impact Analysis
5.6.3.1. Revenue By Class
5.6.3.2. Revenue By Country
5.6.4. 2020 Market Scenario
5.6.5. Quarter by Quarter Forecast
5.6.6. Projected recovery Quarter
5.6.7. Recovery Scenario – Short term, Midterm and Long Term Impact
The post Injectable Benzodiazepine Market is Anticipated to Gain CAGR of 2.7% by 2030 first appeared on Market Research Blog.
Global injectable benzodiazepine sales are set to reach USD 260 million in 2020, as covid-19 panic and uncertainty has set in, even among population with no previous history of mental illnesses, according to a new study by Future Market Insights (FMI). The market research firm estimates the market to grow at 2.7% CAGR through 2030.
Although covid-19 will create a short-term spike, in the long run, the market is likely to be driven by increasing demand for generic drugs. Growing acceptance of injectables as a route of administration is also likely to drive growth.
Key Takeaways of Injectable Benzodiazepine Market Study
- Lorazepam injectable benzodiazepine accounted for the highest share in the injectable benzodiazepine market in 2019
- Seizures and anxiety among leading ailments where injectable benzodiazepines are administered
- North America and Europe are expected to hold a noteworthy revenue share of about 60% in the global injectable benzodiazepine market in 2020
Low cost manufacturing and large patient pools in Asian countries expected to be a key growth driver in the forecast period
“Growing incidences of seizures and anxiety followed by demand for generics to boost the global injectable benzodiazepine market,” says an FMI Analyst.
Request For Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-11724
Research Collaborations: Key to Sustenance
The market players are emphasizing on expanding their manufacturing facilities with introduction of cost-effective and generic drugs and also venturing into strategic partnerships.
- In Jan 2020, Hospital Sales Force from Xellia signed an agreement with Eton to promote Biorphen in the institutions that prefer having ready-to-use injectable formulations
- In Oct 2019, KemPharm’s APADAZ (to treat ADHD) got licensed to KVK-Tech, Inc. to make its generic AG-APADAZ available all across the US
- In Dec 2018, Hikma Pharmaceuticals came up with clobazam oral suspension as well as tablets, the generic equivalent to “Onfi” (marketed by H. Lundbeck A/S)
What else is in the report?
Future market insights offer a unique perspective and actionable insights on injectable benzodiazepine market in its latest study, presenting historical demand assessment from 2015 – 2019 and projections from 2020–2030 based on drug class (diazepam, lorazepam, and midazolam), by time of action (short acting long acting), by indication (agitation & aggression, anxiety, alcohol withdrawal, muscle spasm, seizures, tetanus, sedation, anesthesia insomnia, and status epilepticus), by distribution channel (hospital pharmacies, retail pharmacies and online pharmacies) in seven key regions.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Market Background
4.1. Macro-Economic Factors
4.1.1. Global GDP Growth Outlook
4.1.2. Per Capita Healthcare Expenditure Outlook
4.1.3. Overall Psychoactive Drugs Market
4.2. Forecast Factors – Relevance & Impact
4.2.1. Increasing Incidence of Anxiety, Seizures, Insomnia
4.2.2. Increasing Usage as Anaesthesia
4.2.3. Dose Per Case
4.2.4. Treatment Cost
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
5. Market Context
5.1. Product Adoption / Usage Analysis By Indication
5.2. Disease Epidemiology, By Region
5.3. Regulatory Scenario
5.4. Reimbursement Landscape
5.5. Key Promotional Strategies, By Manufacturers
5.6. COVID19 Crisis Analysis
5.6.1. Current COVID19 Statistics and Probable Future Impact
5.6.2. Current GDP Projection and Probable Impact
5.6.3. COVID19 and Impact Analysis
5.6.3.1. Revenue By Class
5.6.3.2. Revenue By Country
5.6.4. 2020 Market Scenario
5.6.5. Quarter by Quarter Forecast
5.6.6. Projected recovery Quarter
5.6.7. Recovery Scenario – Short term, Midterm and Long Term Impact
The post Injectable Benzodiazepine Market is Anticipated to Gain CAGR of 2.7% by 2030 first appeared on Market Research Blog.
